ArticleJournal of cosmetic dermatology2022
Incidence and treatment of delayed-onset nodules after VYC filler injections to 2139 patients at a single Canadian clinic.
Article in Journal of cosmetic dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- VYC-17.5L is Safe and Effective in Improving Skin Quality and Volume Deficit of Hands: Results From an 18-Month Open-Label Study.Journal of cosmetic dermatology · 2026Article
- Aesthetic Treatment Considerations in Patients with Cutaneous Autoimmune Disease.The Journal of clinical and aesthetic dermatology · 2025Review
- Late-Onset Reactions after Hyaluronic Acid Dermal Fillers: A Consensus Recommendation on Etiology, Prevention and Management.Dermatology and therapy · 2024Review
- A Scoping Review of Hyaluronidase Use in Managing the Complications of Aesthetic Interventions.Aesthetic plastic surgery · 2024Article
- Making Sense of Late Tissue Nodules Associated With Hyaluronic Acid Injections.Aesthetic surgery journal · 2023Article
- Skin Cell and Tissue Responses to Cross-Linked Hyaluronic Acid in Low-Grade Inflammatory Conditions.International journal of inflammation · 2023Article
- Incidence and treatment of delayed-onset nodules after VYC filler injections to 2139 patients at a single Canadian clinic.Journal of cosmetic dermatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData suggest that hyaluronic acid (HA) fillers using VYC technology have a higher incidence of delayed-onset nodule development at facial injection sites than earlier HA products.
objectiveTo assess the incidence of delayed-onset nodules with VYC products based on a single experienced injector. METHODS AND MATERIALS: Patients with delayed-onset nodules after injections with VYC-20L, VYC-17.5L, and VYC-15L were identified by retrospective chart review.
resultsSince 2010, 2139 patients received injections from the same physician with combinations of VYC-20L (57.6% of patients; 2.4 syringes/patient), VYC-17.5L (23.9%; 1.5), or VYC-15L (18.5%; 1.5). Seven female patients (mean age, 62 years) developed delayed-onset nodules for an overall incidence of 0.33%. A potential inflammatory trigger (reported by 6 patients) occurred 1-168 days prior to nodule development. Nodule biopsy in 1 patient confirmed a foreign-body granuloma. The most effective treatment incorporated prednisone with or without hyaluronidase, and in 2 patients, nodules resolved spontaneously. The incidence of delayed-onset nodules was not associated with injection technique or amount of product used.
conclusionVYC-associated incidence of delayed-onset nodules (0.33%) was lower than earlier estimates from previous studies. In the current analysis, VYC-15L had a rate of delayed reactions comparable with non-VYC products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.